2030 年肌肉鬆弛剂市场预测：按药物类型、剂型、给药途径、通路、应用、最终用户和地区进行的全球分析

根据 Stratistics MRC 的数据，2023 年全球肌肉鬆弛剂市场规模为 39 亿美元，预计到 2030 年将达到 60.3 亿美元，预测期内复合年增长率为 6.3%。

肌肉鬆弛剂作用于中枢神经系统，针对神经肌肉接头、脊髓和大脑的特定区域，调节与肌肉收缩相关的讯号。肌肉鬆弛剂可有效缓解与拉伤、扭伤和受伤等疾病相关的肌肉骨骼疼痛。这些药物用于治疗多种医疗状况，包括疼痛管理，例如神经病变引起的痉挛、肌肉骨骼损伤和某些类型的慢性疼痛。

根据2021年全球疾病负担（GBD）资料，全球有17.1亿人患有类风湿性关节炎、颈部不适、腰痛、骨折和其他损伤等肌肉骨骼疾病。

老年人口增加

老年人口的增加是肌肉鬆弛剂市场的主要驱动力，加速了需求。随着世界人口高龄化，与老龄化相关的肌肉骨骼疾病（例如关节炎、慢性疼痛和退化性疾病）的盛行率不断增加。这些疾病通常会导致肌肉僵硬、痉挛和不适，需要医疗干预来缓解疼痛并提高运动表现。肌肉鬆弛剂透过缓解肌肉痉挛、减轻疼痛和改善身体功能，在满足这些需求方面发挥重要作用。

副作用

与肌肉鬆弛剂相关的副作用的普遍存在是肌肉鬆弛剂市场的一个重要抑制因素并阻碍其成长。常见的副作用包括嗜睡、头晕以及可能与其他药物的相互作用，影响患者的医嘱遵从性和对治疗的整体满意度。然而，围绕肌肉鬆弛剂的安全性担忧使得医疗保健专业人员对开立这些药物犹豫不决，特别是对于某些患者群体，例如老年人和患有併发症的患者。

增加久坐的生活方式

久坐生活方式的增加是肌肉鬆弛剂市场的关键驱动因素。现代社会趋势的特征是长时间坐着、文书工作和有限的体力活动，导致肌肉骨骼问题的增加。此外，久坐的生活方式与肌肉痉挛、拉伤和慢性疼痛等症状有关，这就需要使用肌肉鬆弛剂来缓解症状，从而推动市场需求。Masu。

替代治疗方法的可用性

患者和医疗保健提供者越来越多地寻求非药物干预措施，例如物理治疗、针灸和运动疗法，作为肌肉鬆弛剂的有效治疗方法替代方案。此外，患者越来越多地寻求促进整体健康并减少药物干预需求的疗法。替代治疗方法的可用性是阻碍市场扩张的主要因素。

COVID-19 的影响

大流行的早期阶段扰乱了药品供应链，影响了肌肉鬆弛剂的生产和分销。然而，随着医疗保健系统适应不断变化的环境，有效疼痛管理和肌肉相关干预措施的需求推动了市场的復苏。大流行引起的生活方式的改变，例如久坐行为的增加和压力引起的肌肉紧张，导致了对肌肉鬆弛剂的持续需求。

预计注射剂市场在预测期内将是最大的市场

注射剂领域估计占最大份额。注射给药途径在旨在诱导肌肉鬆弛的治疗剂的递送中起着关键作用。可注射的肌肉鬆弛剂例如透过肌肉或静脉注射直接给药到血流或目标肌肉组织。此途径具有起效快、给药控制精确等优点，增加了肌鬆药的需求。

骨骼肌鬆弛剂领域预计在预测期内复合年增长率最高

骨骼肌鬆弛剂领域预计将在预测期内出现良好的增长。这些药物作用于脊髓或大脑层面的中枢神经系统，缓解肌肉痉挛、僵硬和相关不适。骨骼肌鬆弛剂的治疗用途多种多样，从治疗肌肉骨骼疾病和痉挛到促进外科手术和增强物理治疗的效果。此外，在手术环境中，骨骼肌鬆弛剂可用作麻醉辅助剂，促进插管，并最大限度地减少手术期间的不自主肌肉运动。

比最大的地区

由于肌肉骨骼疾病盛行率上升、医疗保健服务意识和可近性不断提高，亚太地区在预测期内占据了最大的市场占有率。亚太地区多样化的医疗保健模式表明，人们越来越接受非侵入性治疗方法，包括用于治疗和美容目的的肌肉鬆弛剂。此外，该地区的经济发展提高了医疗保健支出的能力，并支持创新製药解决方案的采用。

复合年增长率最高的地区：

由于强大的医疗基础设施、技术进步和肌肉骨骼疾病的高盛行率，预计欧洲在预测期内将出现有益增长。该地区人口高龄化以及关节炎和肌肉僵硬等与老龄化相关的疾病的流行极大地增加了对肌肉鬆弛剂的需求。此外，该地区的医疗保健系统优先考虑以患者为中心的护理，并有助于探索肌肉骨骼疾病的创新治疗方案。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

• 公司简介
  • 其他市场公司的综合分析（最多 3 家公司）
  • 主要企业SWOT分析（最多3家企业）
• 区域分割
  • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
• 竞争基准化分析
  • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

• 概述
• 相关利益者
• 调查范围
• 调查方法
  • 资料探勘
  • 资料分析
  • 资料检验
  • 研究途径
• 调查来源
  • 主要调查来源
  • 二次调查来源
  • 先决条件

第三章市场趋势分析

• 促进因素
• 抑制因素
• 机会
• 威胁
• 应用分析
• 最终用户分析
• 新兴市场
• 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

• 供应商的议价能力
• 买方议价能力
• 替代品的威胁
• 新进入者的威胁
• 竞争公司之间的敌对关係

第五章全球肌肉鬆弛剂市场：依药物类型

• 神经肌肉阻断剂
• 骨骼肌鬆弛剂
• 脸部肌肉鬆弛剂

第六章全球肌肉鬆弛剂市场：按剂型

• 胶囊
• 药片
• 液体
• 喷
• 凝胶/软膏

第七章全球肌肉鬆弛剂市场：依给药途径

• 注射
• 口服
• 其他给药途径

第八章全球肌肉鬆弛剂市场：依配销通路

• 零售药房
• 网路药房
• 医院药房

第九章全球肌肉鬆弛剂市场：依应用分类

• 肌肉骨骼疾病
• 肌肉痉挛和疼痛缓解
• 外科手术
• 其他用途

第十章全球肌肉鬆弛剂市场：依最终用户分类

• 专科诊所
• 医院
• 居家护理
• 其他最终用户

第十一章全球肌肉鬆弛剂市场：按地区

• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 纽西兰
  • 韩国
  • 其他亚太地区
• 南美洲
  • 阿根廷
  • 巴西
  • 智利
  • 南美洲其他地区
• 中东/非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 卡达
  • 南非
  • 其他中东/非洲

第十二章 主要进展

• 合约、伙伴关係、协作和合资企业
• 收购和合併
• 新产品发布
• 业务扩展
• 其他关键策略

第十三章 公司简介

• Mylan
• Novartis AG
• Ipsen Biopharmaceuticals, Inc.
• Pfizer Inc
• Merz Pharmaceuticals, LLC.
• Vertical Pharmaceuticals
• Amneal Pharmaceuticals LLC
• Sanofi
• Teva Pharmaceuticals Industries Ltd, Inc.
• Par Pharmaceutical
• Sun Pharmaceutical Industries Ltd.
• Abbott Laboratories
• F. Hoffmann-La Roche AG

According to Stratistics MRC, the Global Muscle Relaxant Drug Market is accounted for $3.9 billion in 2023 and is expected to reach $6.03 billion by 2030 growing at a CAGR of 6.3% during the forecast period. Muscle relaxant drugs act on the central nervous system, targeting neuromuscular junctions, the spinal cord, or specific areas of the brain to modulate signals involved in muscle contraction. Muscle relaxants are effective in providing relief from musculoskeletal pain associated with conditions such as strains, sprains, and injuries. These drugs are utilized in various medical conditions, including the management of conditions such as spasticity resulting from neurological disorders, musculoskeletal injuries, and certain types of chronic pain.

According to a study of Global Burden of Disease (GBD) 2021 data, 1.71 billion individuals globally suffer from musculoskeletal diseases, such as osteoarthritis, rheumatoid arthritis, neck discomfort, low back pain, fractures, and other injuries.

Market Dynamics:

Driver:

Growing geriatric population

The growing geriatric population is a significant driver in the muscle relaxant drug market, accelerating the demand. As the global population ages, there is an increased prevalence of age-related musculoskeletal conditions, such as arthritis, chronic pain, and degenerative disorders. These conditions often result in muscle stiffness, spasms, and discomfort, requiring medical intervention for pain relief and improved mobility. Muscle relaxant drugs play a crucial role in addressing these needs by providing relief from muscle spasms, reducing pain and improving physical function.

Restraint:

Side effects

The prevalence of side effects associated with muscle relaxant drugs stands as a substantial restraint in the muscle relaxant drug market, hampering its growth. Common side effects include drowsiness, dizziness, and potential interactions with other medications, impacting patient adherence and overall satisfaction with treatment. However, safety concerns surrounding muscle relaxants can lead to hesitancy among healthcare providers in prescribing these drugs, especially to certain patient populations, such as the elderly or those with co-morbidities.

Opportunity:

Rising prevalence of sedentary lifestyles

The increasing prevalence of sedentary lifestyles serves as a significant driver for the muscle relaxant drug market. Modern societal trends, characterized by prolonged periods of sitting, desk-bound work and limited physical activity, contribute to a rise in musculoskeletal issues. Furthermore, sedentary lifestyles are linked to conditions such as muscle spasms, strains, and chronic pain, necessitating the use of muscle relaxant drugs for symptomatic relief, which enhances market demand.

Threat:

Availability of alternative treatment modalities

Patients and healthcare providers increasingly explore non-pharmacological interventions, such as physical therapy, acupuncture, and exercise regimens, as viable alternatives to muscle relaxant drugs. Moreover, patients are becoming more proactive in seeking therapies that promote overall well-being and mitigate the need for pharmacological interventions. The availability of alternative treatment modalities is a significant restraint hindering market expansion.

COVID-19 Impact

The initial phase of the pandemic led to disruptions in the pharmaceutical supply chain, affecting the production and distribution of muscle relaxant drugs. However, as healthcare systems adapted to the evolving circumstances, the market witnessed a resurgence driven by the need for effective pain management and muscle-related interventions. The pandemic-induced lifestyle changes, including increased sedentary behaviors and stress-related muscle tension, contributed to a sustained demand for muscle relaxant medications.

The Injectable segment is expected to be the largest during the forecast period

The Injectable segment is estimated to hold the largest share. The Injectable route of administration plays a pivotal role in the delivery of therapeutic agents designed to induce muscle relaxation. Injectable muscle relaxants are administered directly into the bloodstream or targeted muscle tissues through methods such as intramuscular or intravenous injections. This route offers several advantages, including a quick onset of action and accurate dosage control, which enhances the demand for muscle relaxant drugs.

The skeletal muscle relaxant drugs segment is expected to have the highest CAGR during the forecast period

The skeletal muscle relaxant drugs segment is anticipated to have lucrative growth during the forecast period. These drugs act on the central nervous system, either at the spinal cord or brain levels, to alleviate muscle spasms, stiffness, and associated discomfort. The therapeutic applications of skeletal muscle relaxants are diverse, ranging from the management of musculoskeletal conditions and spasticity to facilitating surgical procedures and promoting physical therapy outcomes. Moreover, in surgical settings, skeletal muscle relaxants find utility as adjuncts to anaesthesia, facilitating intubation and minimizing involuntary muscle movements during procedures.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to rising prevalence of musculoskeletal disorders and increasing awareness and accessibility to healthcare services. The Asia-Pacific region's diverse healthcare landscape witnesses a growing acceptance of non-invasive treatment modalities, including muscle relaxants, both for therapeutic and cosmetic purposes. Additionally, the region's economic development results in an increasing capacity for healthcare spending, supporting the adoption of innovative pharmaceutical solutions.

Region with highest CAGR:

Europe is expected to witness profitable growth over the projection period, due to robust healthcare infrastructure, technological advancements, and a high prevalence of musculoskeletal disorders. The region's aging population contributes significantly to the demand for muscle relaxant drugs as age-related conditions, such as arthritis and muscle stiffness, become more prevalent. Moreover, the region's healthcare systems prioritize patient-centric care, contributing to the exploration of innovative treatment options for musculoskeletal conditions.

Key players in the market:

Some of the key players in the Muscle Relaxant Drug Market include Mylan, Novartis AG, Ipsen Biopharmaceuticals, Inc., Pfizer Inc, Merz Pharmaceuticals, LLC., Vertical Pharmaceuticals, Amneal Pharmaceuticals LLC, Sanofi, Teva Pharmaceuticals Industries Ltd, Inc., Par Pharmaceutical, Sun Pharmaceutical Industries Ltd., Abbott Laboratories and F. Hoffmann-La Roche AG.

Key Developments:

In Mar 2023, Abbott partners with Medinbox to increase efficiency in electrophysiology labs and strengthen information sharing among physicians to drive improved patient care.

In June 2022, Novartis announced a partnership with the American Society of Hematology (ASH) to provide six additional African nations with technology that is already being used in Ghana to document and share the diagnosis of babies with sickle cell disease.

In January 2021, Novartis announced collaboration with Alnylam to leverage Alnylam's proven, proprietary siRNA technology to inhibit a target discovered at the Novartis Institutes for BioMedical Research, potentially leading to development of a treatment designed to promote the regrowth of functional liver cells and to provide an alternative to transplantation for patients with liver failure.

Drug Types Covered:

• Neuromuscular Blocking Agents
• Skeletal Muscle Relaxant Drugs
• Facial Muscle Relaxant Drugs

Dosage Forms Covered:

• Capsule
• Tablet
• Liquid
• Sprays
• Gel and Ointments

Route Of Administrations Covered:

• Injectable
• Oral
• Other Route Of Administration

Distribution Channels Covered:

• Retail Pharmacy
• Online Pharmacy
• Hospital Pharmacy

Applications Covered:

• Musculoskeletal Disorders
• Muscle Spasm & Pain Relief
• Surgery
• Other Applications

End Users Covered:

• Specialty Clinics
• Hospitals
• Homecare
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Muscle Relaxant Drug Market, By Drug Type

• 5.1 Introduction
• 5.2 Neuromuscular Blocking Agents
• 5.3 Skeletal Muscle Relaxant Drugs
• 5.4 Facial Muscle Relaxant Drugs

6 Global Muscle Relaxant Drug Market, By Dosage Form

• 6.1 Introduction
• 6.2 Capsule
• 6.3 Tablet
• 6.4 Liquid
• 6.5 Sprays
• 6.6 Gel and Ointments

7 Global Muscle Relaxant Drug Market, By Route Of Administration

• 7.1 Introduction
• 7.2 Injectable
• 7.3 Oral
• 7.4 Other Route Of Administration

8 Global Muscle Relaxant Drug Market, By Distribution Channel

• 8.1 Introduction
• 8.2 Retail Pharmacy
• 8.3 Online Pharmacy
• 8.4 Hospital Pharmacy

9 Global Muscle Relaxant Drug Market, By Application

• 9.1 Introduction
• 9.2 Musculoskeletal Disorders
• 9.3 Muscle Spasm & Pain Relief
• 9.4 Surgery
• 9.5 Other Applications

10 Global Muscle Relaxant Drug Market, By End User

• 10.1 Introduction
• 10.2 Specialty Clinics
• 10.3 Hospitals
• 10.4 Homecare
• 10.5 Other End Users

11 Global Muscle Relaxant Drug Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Mylan
• 13.2 Novartis AG
• 13.3 Ipsen Biopharmaceuticals, Inc.
• 13.4 Pfizer Inc
• 13.5 Merz Pharmaceuticals, LLC.
• 13.6 Vertical Pharmaceuticals
• 13.7 Amneal Pharmaceuticals LLC
• 13.8 Sanofi
• 13.9 Teva Pharmaceuticals Industries Ltd, Inc.
• 13.10 Par Pharmaceutical
• 13.11 Sun Pharmaceutical Industries Ltd.
• 13.12 Abbott Laboratories
• 13.13 F. Hoffmann-La Roche AG

List of Tables

• Table 1 Global Muscle Relaxant Drug Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Muscle Relaxant Drug Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 3 Global Muscle Relaxant Drug Market Outlook, By Neuromuscular Blocking Agents (2021-2030) ($MN)
• Table 4 Global Muscle Relaxant Drug Market Outlook, By Skeletal Muscle Relaxant Drugs (2021-2030) ($MN)
• Table 5 Global Muscle Relaxant Drug Market Outlook, By Facial Muscle Relaxant Drugs (2021-2030) ($MN)
• Table 6 Global Muscle Relaxant Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
• Table 7 Global Muscle Relaxant Drug Market Outlook, By Capsule (2021-2030) ($MN)
• Table 8 Global Muscle Relaxant Drug Market Outlook, By Tablet (2021-2030) ($MN)
• Table 9 Global Muscle Relaxant Drug Market Outlook, By Liquid (2021-2030) ($MN)
• Table 10 Global Muscle Relaxant Drug Market Outlook, By Sprays (2021-2030) ($MN)
• Table 11 Global Muscle Relaxant Drug Market Outlook, By Gel and Ointments (2021-2030) ($MN)
• Table 12 Global Muscle Relaxant Drug Market Outlook, By Route Of Administration (2021-2030) ($MN)
• Table 13 Global Muscle Relaxant Drug Market Outlook, By Injectable (2021-2030) ($MN)
• Table 14 Global Muscle Relaxant Drug Market Outlook, By Oral (2021-2030) ($MN)
• Table 15 Global Muscle Relaxant Drug Market Outlook, By Other Route Of Administration (2021-2030) ($MN)
• Table 16 Global Muscle Relaxant Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 17 Global Muscle Relaxant Drug Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
• Table 18 Global Muscle Relaxant Drug Market Outlook, By Online Pharmacy (2021-2030) ($MN)
• Table 19 Global Muscle Relaxant Drug Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
• Table 20 Global Muscle Relaxant Drug Market Outlook, By Application (2021-2030) ($MN)
• Table 21 Global Muscle Relaxant Drug Market Outlook, By Musculoskeletal Disorders (2021-2030) ($MN)
• Table 22 Global Muscle Relaxant Drug Market Outlook, By Muscle Spasm & Pain Relief (2021-2030) ($MN)
• Table 23 Global Muscle Relaxant Drug Market Outlook, By Surgery (2021-2030) ($MN)
• Table 24 Global Muscle Relaxant Drug Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 25 Global Muscle Relaxant Drug Market Outlook, By End User (2021-2030) ($MN)
• Table 26 Global Muscle Relaxant Drug Market Outlook, By Specialty Clinics (2021-2030) ($MN)
• Table 27 Global Muscle Relaxant Drug Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 28 Global Muscle Relaxant Drug Market Outlook, By Homecare (2021-2030) ($MN)
• Table 29 Global Muscle Relaxant Drug Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.